ScholarIQanswers from OpenAlex
Idorsia Pharmaceuticals
FunderResearch funding and supported work
Idorsia Pharmaceuticals is a funder indexed in ScholarIQ from OpenAlex.
What is known about Idorsia Pharmaceuticals?
ScholarIQrecord summary
company in Allschwil, Switzerland
How many works does Idorsia Pharmaceuticals have?
ScholarIQindexed works
Idorsia Pharmaceuticals has 1,079 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Idorsia Pharmaceuticals?
ScholarIQopenalex
The OpenAlex for Idorsia Pharmaceuticals is on the source record.
What is the ROR of Idorsia Pharmaceuticals?
ScholarIQror
The ROR for Idorsia Pharmaceuticals is on the source record.
What are the most-cited papers on Idorsia Pharmaceuticals?
ScholarIQmost cited works
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge, Tak Mao Chan, H. Terence Cook, Fernando C. Fervenza, Keisha L. Gibson, Richard J. Glassock, David Jayne, Vivekanand Jha, Adrian Liew, Zhi-Hong Liu, Juan M. Mejía‐Vilet, Carla Nester, Jai Radhakrishnan, Elizabeth M. Rave, Heather N. Reich, Pierre Ronco, Jan‐Stephan Sanders, Sanjeev Sethi, Yusuke Suzuki, Sydney Tang, Vladimı́r Tesař, Marina Vivarelli, Jack F.M. Wetzels, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Jürgen Floege
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease
Rajiv Agarwal, Bertram Pitt, Biff F. Palmer, Csaba P. Kövesdy, Ellen Burgess, Gerasimos Filippatos, Jolanta Małyszko, Luís M. Ruilope, Patrick Rossignol, Peter Rossing, Roberto Pecoits‐Filho, Stefan D. Anker, Amer Joseph, Robert Lawatscheck, Daniel J. Wilson, Martin Gebel, George L. Bakris
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Adrian F. Hernandez, Jacob A. Udell, W. Schuyler Jones, Stefan D. Anker, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Svenja Seide, Isabella Zwiener, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayés‐Genís, Yundai Chen, Vijay Chopra, Gemma A. Figtree, Junbo Ge, Shaun G. Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gąsior, Waheed Jamal, James L. Januzzi, Myung Ho Jeong, Yu. M. Lopatin, Renato D. Lópes, Béla Merkely, Puja B. Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rosselló, Morten Schou, Dragan Šimić, Philippe Gabríel Steg, Joanna Szachniewicz, Peter van der Meer, Dragoş Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Javed Butler
Patiromer Versus Placebo to Enable Spironolactone Use in Patients with Resistant Hypertension and Chronic Kidney Disease ( <b>AMBER</b> ): Results in the Pre-Specified Subgroup with Heart Failure
Patrick Rossignol, Bryan Williams, Martha Mayo, Suzette Warren, Susan Arthur, Gail Ackourey, William B. White, Rajiv Agarwal
Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
Logan Schneider, Anne Marie Morse, Michael Strunc, Joyce Lee‐Iannotti, Richard Bogan